サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1729121

神経栄養性角膜炎治療の世界市場の機会と戦略（～2034年）

Neurotrophic Keratitis Treatment Global Market Opportunities And Strategies To 2034

出版日
ページ情報
英文 330 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.06円
神経栄養性角膜炎治療の世界市場の機会と戦略（～2034年）
出版日: 2025年05月20日
発行: The Business Research Company
ページ情報: 英文 330 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の神経栄養性角膜炎治療の市場規模は2019年に3億1,369万米ドルであり、2024年まで27.00%を超えるCAGRで成長しました。

糖尿病の高い有病率

糖尿病の高い有病率が、過去の期間に神経栄養性角膜炎治療市場の成長を促進しました。糖尿病患者における慢性的な高血糖は、角膜神経に影響を与える糖尿病性神経障害につながる可能性があり、傷害を検出し反応する能力が損なわれます。これにより、角膜の保護反射や治癒能力が失われ、潰瘍や感染症にかかりやすくなるため、神経栄養性角膜炎を発症する可能性が高くなります。例えば、ベルギーを拠点とする各国の糖尿病協会の統括組織である国際糖尿病連合（IDF）によると、2021年に糖尿病を発症した20～79歳の成人は世界で5億3,700万人に上り、その4分の3超が低中所得国に居住しています。糖尿病による死亡者数は約670万人で、5秒に1人が死亡している計算になります。糖尿病に関連する医療費は9,660億米ドルに達し、過去15年間で316%増加しました。さらに、5億4,100万人の成人が耐糖能異常（IGT）を有し、2型糖尿病の発症リスクを高めています。さらに、米国の国立公衆衛生機関である疾病対策予防センター（CDC）が発表したNational Diabetes Statistics Reportによると、2021年に米国民の11.6%、全年齢で3,840万人が糖尿病を患っています。年齢とともに糖尿病患者の割合は上昇し、65歳以上では29.2%に達しました。したがって、糖尿病の高い有病率が神経栄養性角膜炎治療市場の成長に寄与しました。

当レポートでは、世界の神経栄養性角膜炎治療市場について調査分析し、市場の特徴、各地域の市場規模と予測、競合情勢、市場機会と戦略などの情報を提供しています。

目次

第1章 エグゼクティブサマリー

  • 神経栄養性角膜炎の治療 - 市場の魅力とマクロ経済情勢

第2章 目次

第3章 表のリスト

第4章 図のリスト

第5章 レポートの構成

第6章 市場の特徴

  • 一般的な市場の定義
  • サマリー
  • 神経栄養性角膜炎治療市場の定義とセグメンテーション
  • 市場のセグメンテーション：治療別
    • 局所抗生物質
    • 組み換えヒト神経成長因子（rhNGF）
    • 羊膜移植
    • 角膜移植
    • その他の治療
  • 市場のセグメンテーション：投与経路別
    • 経口
    • 局所
    • その他の投与経路
  • 市場のセグメンテーション：エンドユーザー別
    • 病院
    • 在宅医療
    • 専門クリニック
    • その他のエンドユーザー

第7章 主な市場動向

  • 角膜組織片による円錐角膜治療の革新
  • 革新的な細胞療法が水疱性角膜症患者に新たな希望をもたらす
  • 共同研究によりカナダ初のプリロードDMEK移植が実現する

第8章 世界の神経栄養性角膜炎治療の成長分析、戦略的分析フレームワーク

  • 神経栄養性角膜炎治療のPESTEL分析
  • 最終用途産業の分析
    • 病院
    • 在宅医療
    • 専門センター
    • その他のエンドユーザー
  • 世界の神経栄養性角膜炎治療市場の成長率分析
  • 市場規模
  • 市場成長の実績（2019年～2024年）
    • 市場促進要因（2019年～2024年）
    • 市場抑制要因（2019年～2024年）
  • 市場成長の予測（2024年～2029年・2034年）
    • 市場促進要因（2024年～2029年）
    • 市場抑制要因（2024年～2029年）
  • 成長要因の予測
    • 量的成長要因
    • 促進要因
    • 抑制要因
  • 世界の神経栄養性角膜炎治療の総市場規模（TAM）

第9章 世界の神経栄養性角膜炎治療市場のセグメンテーション

  • 世界の神経栄養性角膜炎治療市場：治療別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場：投与経路別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場：エンドユーザー別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場、局所抗生物質のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場、組換えヒト神経成長因子（rhNGF）のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場、羊膜移植のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場、角膜移植のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場、その他の治療法のサブセグメンテーション：タイプ別、実績と予測（2019年～2024年・2029年・2034年）

第10章 神経栄養性角膜炎治療市場、地域と国の分析

  • 世界の神経栄養性角膜炎治療市場：地域別、実績と予測（2019年～2024年・2029年・2034年）
  • 世界の神経栄養性角膜炎治療市場：国別、実績と予測（2019年～2024年・2029年・2034年）

第11章 アジア太平洋市場

第12章 西欧市場

第13章 東欧市場

第14章 北米市場

第15章 南米市場

第16章 中東市場

第17章 アフリカ市場

第18章 競合情勢と企業プロファイル

  • 企業プロファイル
  • Dompe Farmaceutici SpA
  • BRIM Biotechnology Inc.
  • Recordati SpA
  • Oyster Point Pharma Inc.
  • HLB Therapeutics Co. Ltd.

第19章 その他の主要企業と革新的企業

  • Neuroptika Inc.
  • Aurolab
  • ReGenTree LLC
  • Claris Biotherapeutics Inc.
  • Mime Tech
  • RegeneRx Biopharmaceuticals

第20章 競合ベンチマーキング

第21章 競合ダッシュボード

第22章 主な合併と買収

  • Bausch+Lomb Acquired Novartis AG
  • HLB Group Acquired RegeneRx Biopharmaceuticals Inc

第23章 機会と戦略

  • 世界の神経栄養性角膜炎治療市場 - もっとも新たな機会を提供する国（2029年）
  • 世界の神経栄養性角膜炎治療市場 - もっとも新たな機会を提供するセグメント（2029年）
  • 世界の神経栄養性角膜炎治療市場 - 成長戦略（2029年）
    • 市場動向に基づく戦略
    • 競合の戦略

第24章 神経栄養性角膜炎治療市場：結論と提言

  • 結論
  • 提言
    • 製品
    • 流通
    • 価格
    • 販促
    • 人々

第25章 付録

目次
Product Code: o&s1563

Neurotrophic keratitis treatment refers to the therapies and medical interventions designed to manage and treat neurotrophic keratitis (NK), a rare degenerative disease of the cornea caused by impaired corneal nerve function. This condition leads to decreased or absent corneal sensation, resulting in impaired healing, persistent epithelial defects and corneal ulceration, which can progress to perforation in severe cases. comprises pharmaceutical drugs, surgical interventions and regenerative therapies aimed at restoring corneal integrity, preventing complications and improving patients' vision and quality of life.

The neurotrophic keratitis treatment market consists of sales of neurotrophic keratitis treatments and related services by entities (organizations, sole traders and partnerships) that develop and provide treatments to address the underlying nerve damage, promote corneal healing and prevent disease progression. The use of neurotrophic keratitis treatments depends on the severity of the disease, which is classified into three stages: early-stage epithelial irregularities (Stage I), persistent epithelial defects (Stage II) and corneal ulceration or perforation (Stage III).

The global neurotrophic keratitis treatment market was valued at $313.69 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 27.00%.

High Prevalence Of Diabetes

The high prevalence of diabetes drove the growth of the neurotrophic keratitis treatment market during the historic period. Chronic hyperglycemia in diabetic patients can lead to diabetic neuropathy, which affects the corneal nerves, impairing their ability to detect and respond to injuries. This increases the likelihood of developing neurotrophic keratitis, as the cornea loses its protective reflexes and healing capacity, making it more vulnerable to ulcers and infections. For example, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organization of national diabetes associations, diabetes affected 537 million adults aged 20-79 worldwide in 2021, with over three-quarters residing in low- and middle-income countries. The disease caused approximately 6.7 million deaths, equating to one death every five seconds. Health expenditures related to diabetes reached USD 966 billion, marking a 316% increase over the past 15 years. Further, 541 million adults had impaired glucose tolerance (IGT), heightening their risk of developing type 2 diabetes. Additionally, according to the National Diabetes Statistics Report published by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, 11.6% of US citizens or 38.4 million people of all ages, suffered from diabetes in 2021. With age, the percentage of people with diabetes rose and among those 65 years of age or older, it reached 29.2%. Therefore, the high prevalence of diabetes contributed to the growth of the neurotrophic keratitis treatment market.

Revolutionizing Keratoconus Treatment With Contoured Corneal Tissue Segments

Major companies operating in the neurotrophic keratitis treatment market are focusing on revolutionizing keratoconus treatment with contoured corneal tissue segments. By developing contoured corneal tissue segments, companies aim to improve the structural integrity of the cornea while also potentially promoting nerve regeneration and better healing. These segments can be precisely designed to match the patient's specific corneal anatomy, offering a personalized treatment approach that enhances both mechanical stability and sensory function. For instance, in June 2024, CorneaGen, a US-based developer of medical devices, launched the Corneal Tissue Addition for Keratoplasty (CTAK), a solution designed for corneal contouring in keratoconic eyes. CTAK provides patient-ready, gamma-irradiated, sterile, non-immunogenic corneal tissue segments, laser-cut and customized to the patient's specific cone severity and location. This advancement aims to improve surgical outcomes and make optimal use of corneal donations.

The global neurotrophic keratitis treatment market is highly concentrated, with large player dominating the market. The top 1 competitor in the market made up 100% of the total market in 2023.

Neurotrophic Keratitis Treatment Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global neurotrophic keratitis treatment market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for neurotrophic keratitis treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The neurotrophic keratitis treatment market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider neurotrophic keratitis treatment market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment, by route of administration and by end-user.
  • Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment, by route of administration and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth - Regional market size forecast (2030-2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard - Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Recent Developments - Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for neurotrophic keratitis treatment providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (RhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
  • 2) By Route Of Administration: Oral; Topical; Other Routes Of Administration
  • 3) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Companies Mentioned: Dompe Farmaceutici S.p.A.; BRIM Biotechnology Inc.; Recordati S.p.A; Oyster Point Pharma Inc.; HLB Therapeutics Co. Ltd.
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; neurotrophic keratitis treatment indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Neurotrophic Keratitis Treatment - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Neurotrophic Keratitis Treatment Market Definition And Segmentations
  • 6.4 Market Segmentation By Treatment
    • 6.4.1 Topical Antibiotics
    • 6.4.2 Recombinant Human Nerve Growth Factor (rhNGF)
    • 6.4.3 Amniotic Membrane Transplantation
    • 6.4.4 Keratoplasty
    • 6.4.5 Other Treatments
  • 6.5 Market Segmentation By Route of Administration
    • 6.5.1 Oral
    • 6.5.2 Topical
    • 6.5.3 Other Routes of Administration
  • 6.6 Market Segmentation By End-User
    • 6.6.1 Hospitals
    • 6.6.2 Homecare
    • 6.6.3 Specialty Clinics
    • 6.6.4 Other End-Users

7 Major Market Trends

  • 7.1 Revolutionizing Keratoconus Treatment With Contoured Corneal Tissue Segments
  • 7.2 Innovative Cell Therapy Brings New Hope To Bullous Keratopathy Patients
  • 7.3 Research Collaboration Leads to Canada's First Preloaded DMEK Transplant

8 Global Neurotrophic Keratitis Treatment Growth Analysis And Strategic Analysis Framework

  • 8.1 Global Neurotrophic Keratitis Treatment PESTEL Analysis
    • 8.1.1 Political
    • 8.1.2 Economic
    • 8.1.3 Social
    • 8.1.4 Technological
    • 8.1.5 Environmental
    • 8.1.6 Legal
  • 8.2 Analysis Of End User Industries
    • 8.2.1 Hospitals
    • 8.2.2 Home Care
    • 8.2.3 Specialty Centers
    • 8.2.4 Other End Users
  • 8.3 Global Neurotrophic Keratitis Treatment Market Growth Rate Analysis
  • 8.4 Market Size
  • 8.5 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 8.5.1 Market Drivers 2019 - 2024
    • 8.5.2 Market Restraints 2019 - 2024
  • 8.6 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
    • 8.6.1 Market Drivers 2024 - 2029
    • 8.6.2 Market Restraints 2024 - 2029
  • 8.7 Forecast Growth Contributors/Factors
    • 8.7.1 Quantitative Growth Contributors
    • 8.7.2 Drivers
    • 8.7.3 Restraints
  • 8.8 Global Neurotrophic Keratitis Treatment Total Addressable Market (TAM)

9 Global Neurotrophic Keratitis Treatment Market Segmentation

  • 9.1 Global Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.2 Global Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.3 Global Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.4 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Topical Antibiotics, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.5 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Recombinant Human Nerve Growth Factor (rhNGF), By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.6 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Amniotic Membrane Transplantation, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.7 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Keratoplasty, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 9.8 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Other Treatments, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Neurotrophic Keratitis Treatment Market, Regional and Country Analysis

  • 10.1 Global Neurotrophic Keratitis Treatment Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.2 Global Neurotrophic Keratitis Treatment Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

  • 11.1 Summary
  • 11.2 Market Overview
    • 11.2.1 Region Information
    • 11.2.2 Market Information
    • 11.2.3 Background Information
    • 11.2.4 Government Initiatives
    • 11.2.5 Regulations
    • 11.2.6 Regulatory Bodies
    • 11.2.7 Major Associations
    • 11.2.8 Taxes Levied
    • 11.2.9 Corporate Tax Structure
    • 11.2.10 Investments
    • 11.2.11 Major Companies
  • 11.3 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.4 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.5 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.6 Asia-Pacific Neurotrophic Keratitis Treatment Market: Country Analysis
  • 11.7 China Market
  • 11.8 Summary
  • 11.9 Market Overview
    • 11.9.1 Country Information
    • 11.9.2 Market Information
    • 11.9.3 Background Information
    • 11.9.4 Government Initiatives
    • 11.9.5 Regulations
    • 11.9.6 Regulatory Bodies
    • 11.9.7 Major Associations
    • 11.9.8 Taxes Levied
    • 11.9.9 Corporate Tax Structure
    • 11.9.10 Major Companies
  • 11.10 China Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.11 China Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.12 China Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.13 India Market
  • 11.14 India Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.15 India Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.16 India Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.17 Japan Market
  • 11.18 Market Overview
    • 11.18.1 Country Information
    • 11.18.2 Market Information
    • 11.18.3 Background Information
    • 11.18.4 Government Initiatives
    • 11.18.5 Regulations
    • 11.18.6 Regulatory Bodies
    • 11.18.7 Major Associations
    • 11.18.8 Taxes Levied
    • 11.18.9 Corporate Tax Structure
    • 11.18.10 Investments
    • 11.18.11 Major Companies
  • 11.19 Japan Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.20 Japan Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.21 Japan Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.22 Australia Market
  • 11.23 Australia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.24 Australia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.25 Australia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.26 Indonesia Market
  • 11.27 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.28 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.29 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.30 South Korea Market
  • 11.31 Market Overview
    • 11.31.1 Country Information
    • 11.31.2 Market Information
    • 11.31.3 Background Information
    • 11.31.4 Government Initiatives
    • 11.31.5 Regulations
    • 11.31.6 Regulatory Bodies
    • 11.31.7 Major Associations
    • 11.31.8 Taxes Levied
    • 11.31.9 Corporate Tax Structure
    • 11.31.10 Investment
    • 11.31.11 Major Companies
  • 11.32 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.33 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.34 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

  • 12.1 Summary
  • 12.2 Market Overview
    • 12.2.1 Region Information
    • 12.2.2 Market Information
    • 12.2.3 Background Information
    • 12.2.4 Government Initiatives
    • 12.2.5 Regulations
    • 12.2.6 Regulatory Bodies
    • 12.2.7 Major Associations
    • 12.2.8 Taxes Levied
    • 12.2.9 Corporate tax structure
    • 12.2.10 Investments
    • 12.2.11 Major Companies
  • 12.3 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.4 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.5 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.6 Western Europe Neurotrophic Keratitis Treatment Market: Country Analysis
  • 12.7 UK Market
  • 12.8 UK Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.9 UK Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.10 UK Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.11 Germany Market
  • 12.12 Germany Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.13 Germany Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.14 Germany Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.15 France Market
  • 12.16 France Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.17 France Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.18 France Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.19 Italy Market
  • 12.20 Italy Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.21 Italy Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.22 Italy Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.23 Spain Market
  • 12.24 Spain Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.25 Spain Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.26 Spain Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

  • 13.1 Summary
  • 13.2 Market Overview
    • 13.2.1 Region Information
    • 13.2.2 Market Information
    • 13.2.3 Background Information
    • 13.2.4 Government Initiatives
    • 13.2.5 Regulations
    • 13.2.6 Regulatory Bodies
    • 13.2.7 Major Associations
    • 13.2.8 Taxes Levied
    • 13.2.9 Corporate Tax Structure
    • 13.2.10 Major companies
  • 13.3 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.4 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.5 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.6 Eastern Europe Neurotrophic Keratitis Treatment Market: Country Analysis
  • 13.7 Russia Market
  • 13.8 Russia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.9 Russia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.10 Russia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

  • 14.1 Summary
  • 14.2 Market Overview
    • 14.2.1 Region Information
    • 14.2.2 Market Information
    • 14.2.3 Background Information
    • 14.2.4 Government Initiatives
    • 14.2.5 Regulations
    • 14.2.6 Regulatory Bodies
    • 14.2.7 Major Associations
    • 14.2.8 Taxes Levied
    • 14.2.9 Corporate Tax Structure
    • 14.2.10 Investments
    • 14.2.11 Major Companies
  • 14.3 North America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.4 North America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.5 North America Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.6 North America Neurotrophic Keratitis Treatment Market: Country Analysis
  • 14.7 USA Market
  • 14.8 Summary
  • 14.9 Market Overview
    • 14.9.1 Country Information
    • 14.9.2 Market Information
    • 14.9.3 Background Information
    • 14.9.4 Government Initiatives
    • 14.9.5 Regulations
    • 14.9.6 Regulatory Bodies
    • 14.9.7 Major Associations
    • 14.9.8 Taxes Levied
    • 14.9.9 Corporate Tax Structure
    • 14.9.10 Investments
    • 14.9.11 Major Companies
  • 14.10 USA Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.11 USA Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.12 USA Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.13 Canada Market
  • 14.14 Summary
  • 14.15 Market Overview
    • 14.15.1 Country Information
    • 14.15.2 Market Information
    • 14.15.3 Background Information
    • 14.15.4 Government Initiatives
    • 14.15.5 Regulations
    • 14.15.6 Regulatory Bodies
    • 14.15.7 Major Associations
    • 14.15.8 Taxes Levied
    • 14.15.9 Corporate Tax Structure
    • 14.15.10 Investments
    • 14.15.11 Major Companies
  • 14.16 Canada Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.17 Canada Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.18 Canada Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

  • 15.1 Summary
  • 15.1 Market Overview
    • 15.1.1 Region Information
    • 15.1.2 Market Information
    • 15.1.3 Background Information
    • 15.1.4 Government Initiatives
    • 15.1.5 Regulations
    • 15.1.6 Regulatory Bodies
    • 15.1.7 Major Associations
    • 15.1.8 Taxes Levied
    • 15.1.9 Corporate Tax Structure
    • 15.1.10 Major Companies
  • 15.2 South America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.3 South America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.4 South America Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.5 South America Neurotrophic Keratitis Treatment Market: Country Analysis
  • 15.6 Brazil Market
  • 15.7 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.8 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.9 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

  • 16.1 Summary
  • 16.2 Market Overview
    • 16.2.1 Region Information
    • 16.2.2 Market Information
    • 16.2.3 Background Information
    • 16.2.4 Government Initiatives
    • 16.2.5 Regulations
    • 16.2.6 Regulatory Bodies
    • 16.2.7 Major Associations
    • 16.2.8 Taxes Levied
    • 16.2.9 Corporate Tax Structure
    • 16.2.10 Major Companies
  • 16.3 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.4 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.5 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

  • 17.1 Summary
  • 17.2 Market Overview
    • 17.2.1 Region Information
    • 17.2.2 Market Information
    • 17.2.3 Background Information
    • 17.2.4 Government Initiatives
    • 17.2.5 Regulations
    • 17.2.6 Regulatory Bodies
    • 17.2.7 Major Associations
    • 17.2.8 Taxes Levied
    • 17.2.9 Corporate Tax Structure
    • 17.2.10 Major Companies
  • 17.3 Africa Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.4 Africa Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.5 Africa Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape And Company Profiles

  • 18.1 Company Profiles
  • 18.2 Dompe Farmaceutici S.p.A.
    • 18.2.1 Company Overview
    • 18.2.2 Products And Services
    • 18.2.3 Business Strategy
    • 18.2.4 Financial Overview
  • 18.3 BRIM Biotechnology Inc.
    • 18.3.1 Company Overview
    • 18.3.2 Products And Services
    • 18.3.3 Business Strategy
    • 18.3.4 Financial Overview
  • 18.4 Recordati S.p.A.
    • 18.4.1 Company Overview
    • 18.4.2 Products And Services
    • 18.4.3 Financial Overview
  • 18.5 Oyster Point Pharma Inc.
    • 18.5.1 Company Overview
    • 18.5.2 Products And Services
    • 18.5.3 Business Strategy
    • 18.5.4 Financial Overview
  • 18.6 HLB Therapeutics Co. Ltd.
    • 18.6.1 Company Overview
    • 18.6.2 Products And Services
    • 18.6.3 Financial Overview

19 Other Major And Innovative Companies

  • 19.1 Neuroptika Inc.
    • 19.1.1 Company Overview
    • 19.1.2 Product And Services
  • 19.2 Aurolab
    • 19.2.1 Company Overview
    • 19.2.2 Product And Services
  • 19.3 ReGenTree LLC
    • 19.3.1 Company Overview
    • 19.3.2 Product And Services
  • 19.4 Claris Biotherapeutics Inc.
    • 19.4.1 Company Overview
    • 19.4.2 Product And Services
  • 19.5 Mime Tech
    • 19.5.1 Company Overview
    • 19.5.2 Product And Services
  • 19.6 RegeneRx Biopharmaceuticals
    • 19.6.1 Company Overview
    • 19.6.2 Product And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

  • 22.1 Bausch + Lomb Acquired Novartis AG
  • 22.2 HLB Group Acquired RegeneRx Biopharmaceuticals Inc

23 Opportunities And Strategies

  • 23.1 Global Neurotrophic Keratitis Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 23.2 Global Neurotrophic Keratitis Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 23.3 Global Neurotrophic Keratitis Treatment Market In 2029 - Growth Strategies
    • 23.3.1 Market Trend Based Strategies
    • 23.3.2 Competitor Strategies

24 Neurotrophic Keratitis Treatment Market, Conclusions And Recommendations

  • 24.1 Conclusions
  • 24.2 Recommendations
    • 24.2.1 Product
    • 24.2.2 Place
    • 24.2.3 Price
    • 24.2.4 Promotion
    • 24.2.5 People

25 Appendix

  • 25.1 Geographies Covered
  • 25.2 Market Data Sources
  • 25.3 Research Methodology
  • 25.4 Currencies
  • 25.5 The Business Research Company
  • 25.6 Copyright and Disclaimer